Recent reports have shown that estradiol increases the hypophagic effect of exogenous cholecystokinin-octapeptide (CCK). CCK is known to increase the expression of Fos, a marker of neuronal activation, in specific medullary and hypothalamic nuclei. The present experiment tested the hypothesis that as estradiol enhances the behavioral effects of CCK, there is a parallel amplification of CCK-induced Fos expression. Instead, estradiol pretreatment reduced the level of CCK-induced Fos expression in the nucleus of the solitary tract (NTS) and in the medial parvocellular region of the hypothalamic paraventricular nucleus (PVN). The number of Fos-containing cells in the supraoptic nucleus and other regions of the PVN were not affected by estradiol pretreatment. The results are consistent with the hypothesis that the NTS and/or the PVN may mediate the estrogen-induced increased sensitivity to peripheral inhibitory signals in the control of food intake.

Keywords:
Cholecystokinin, c-Fos, Gonadal steroids, Food intake, Immunocytochemistry, Paraventricular nucleus, Vagus
1.
Tarttelin MF, Gorski RA: The effects of ovarian steroids on food and water intake and body weight in the female rat. Acta Endocrinol 1973;73:551–568.
2.
Wade GN: Some effects of ovarian hormones on food intake and body weight in female rats. J Comp Physiol Psychol 1975;88:183–193.
3.
Butera PC, Beikirch RJ: Central implants of diluted estradiol: Independent effects on ingestion and reproductive behaviors of ovariectomized rats. Brain Res 1989;491:266–273.
4.
Butera PC, Willard DM, Raymond SA: Effects of PVN lesions on the responsiveness of female rats to estradiol. Brain Res 1992;576:304–310.
5.
Butera PC, Campbell RB, Bradway DM: Antagonism of estrogenic effects on feeding behavior by central implants of anisomycin. Brain Res 1993;624:354–356.
6.
Dagnault A, Richard D: Lesions of the hypothalamic paraventricular nuclei do not prevent the effect of estradiol on energy and fat balance. Am J Physiol 1994;267:E32–E38.
7.
Geary N, Trace D, Smith GP: Estradiol interacts with gastric or postgastric food stimuli to decrease sucrose ingestion in ovariectomized rats. Physiol Behav 1995;57:155–158.
8.
Geary N, Trace D, McEwen B, Smith GP: Cyclic estradiol replacement increases the satiety effect of CCK-8 in ovariectomized rats. Physiol Behav 1994;56:281–289.
9.
Ritter RC, Ladenheim EE: Capsaicin pretreatment attenuates suppression of food intake by cholecystokinin. Am J Physiol 1985;248:R501–R504.
10.
Smith GP, Jerome C, Norgren R: Afferent axones in abdominal vagus mediate satiety effect of cholecystokinin in rats. Am J Physiol 1985;249:R638–R641.
11.
McCann MJ, Verbalis JG, Stricker EM: Capsaicin pretreatment attenuates multiple responses to cholecystokinin in rats. J Auton Nerv Syst 1988;23:265–272.
12.
Verbalis JG, Stricker EM, Robinson AG, Hoffman GE: Cholecystokinin activates C-Fos expression in hypothalamic oxytocin and corticotropin-releasing hormone neurons. J Neuroendocrinol 1991;3:205–213.
13.
Olson BR, Hoffman GE, Sved AF, Stricker EM, Verbalis JG: Cholecystokinin induces c-fos expression in hypothalamic oxytocin neurons projecting to the dorsal vagal complex. Brain Res 1992;569:238–248.
14.
Onaka T, Palmer JR, Yagi K: A selective role of brainstem noradrenergic neurons in oxytocin release from the neurohypophysis following noxious stimuli in the rat. Neurosci Res 1996;25:67–75.
15.
Renaud LP, Tang M, McCann MJ, Stricker EM, Verbalis JG: Cholecystokinin and gastric distension activate oxytocinergic cells in the rat hypothalamus. Am J Physiol 1987;253:R661–R665.
16.
Ueta Y, Kannan H, Yamashita H: Gastric afferents to the paraventricular nucleus of the rat. Exp Brain Res 1991;84:487–494.
17.
Watson RE, Weigand SJ, Clough RW, Hoffman GE: Use of cryoprotectant to maintain long-term peptide immunoreactivity and tissue morphology. Peptides 1986;7:155–159.
18.
Sawchenko PE, Swanson LW: Immunohistochemical identification of neurons in the paraventricular nucleus of the hypothalamus that project to the medulla or to the spinal cord in the rat. J Comp Neurol 1982;205:260–272.
19.
Olson BR, Freilino M, Hoffman GE, Stricker EM, Sved AF, Verbalis JG: c-Fos expression in rat brain and brainstem nuclei in response to treatments that alter food intake and gastric motility. Mol Cell Neurosci 1993;4:93–106.
20.
Rinaman L, Verbalis JG, Stricker EM, Hoffman GE: Distribution and neurochemical phenotypes of caudal medullary neurons activated to express cFos following peripheral administration of cholecystokinin. J Comp Neurol 1993;338:475–490.
21.
Dulawa SC, Vanderweele DA: Cholecystokinin and estradiol synergistically potentiate satiety in rats. Peptides 1994;15:913–918.
22.
Grill HJ, Smith GP: Cholecystokinin decreases sucrose intake in chronic decerebrate rats. Am J Physiol 1988;254:R853–R856.
23.
Geary N, Smith GP, Corp ES: The increased satiating potency of CCK-8 by estradiol is not mediated by upregulation of NTS CCK receptors. Brain Res 1996;719:179–186.
24.
Rinaman L, Hoffman GE, Dohanics J, Le W-W, Stricker EM, Verbalis JG: Cholecystokinin activates catecholaminergic neurons in the caudal medulla that innervate the paraventricular nucleus of the hypothalamus in rats. J Comp Neurol 1995;260:1995.
25.
Ricardo JA, Koh ET: Anatomical evidence of a direct projection from the nucleus of the solitary tract to the hypothalamus, amygdala, and other forebrain structures in the rat. Brain Res 1978;153:1–26.
26.
Qian M, Johnson AE, Kallstrom L, Carrer H, Sodersten P: Cholecystokinin, dopamine D2 and N-methyl-D-aspartate binding sites in the nucleus of the solitary tract of the rat: Possible relationship to ingestive behavior. Neuroscience 1997;77:1077–1089.
27.
Heritage AS, Grant LD, Stumpf WE: 3H estradiol in catecholamine neurons of rat brain stem: Combined localization by autoradiography and formaldehyde-induced fluorescence. J Comp Neurol 1977;176:607–630.
28.
Swanson LW, Kuypers HGJM: The paraventricular nucleus of the hypothalamus: cytoarchitectonic subdivisions and organization of projections to the pituitary, dorsal vagal complex, and spinal cord as demonstrated by retrograde fluorescence double-labeling methods. J Comp Neurol 1980;194:555–570.
29.
Sofroniew MV, Schrell U: Evidence for a direct projection from oxytocin and vasopressin neurons in the hypothalamic paraventricular nucleus to the medulla oblongata: Immunohistochemical visualization of both the horseradish peroxidase transported and the peptide produced by the same neurons. Neurosci Lett 1981;22:211–217.
30.
Simerly RB, Chang C, Muramatsu M, Swanson LW: Distribution of androgen and estrogen receptor mRNA-containing cells in the rat brain: An in situ hybridization study. J Comp Neurol 1990;294:76–95.
31.
DonCarlos LL, Monroy E, Morrell JI: Distribution of estrogen receptor-immunoreactive cells in the forebrain of the female guinea pig. J Comp Neurol 1991;305:591–612.
32.
Corodimas KP, Morrell JI: Estradiol-concentrating forebrain and midbrain neurons project directly to the medulla. J Comp Neurol 1990;291:609–620.
33.
Dagnault A, Richard D: Involvement of the medial preoptic area in the anorectic action of estrogens. Am J Physiol 1997;272:R311–R317.
34.
Morley JE, Levine AS: Corticotropin-releasing factor, grooming and ingestive behavior. Life Sci 1982;31:1459–1464.
35.
Kyrkouli SE, Stanley BG, Seirafi RD, Leibowitz SF: Stimulation of feeding by galanin: Anatomical localization and behavioral specificity of this peptide’s effects in the brain. Peptides 1990;11:995–1001.
36.
Stanley BG, Kyrkouli SE, Lampert S, Leibowitz SF: Neuropeptide Y chronically injected into the hypothalamus: A powerful neurochemical inducer of hyperphagia and obesity. Peptides 1986;7:1189–1192.
37.
Arletti R, Benelli A, Bertolini A: Influence of oxytocin on feeding behavior in the rat. Peptides 1989;10:89–93.
38.
Olson BR, Drutarosky MD, Chow M-S, Hruby VJ, Stricker EM, Verbalis JG: Oxytocin and an oxytocin agonist administered centrally decrease food intake in rats. Peptides 1991;12:113–118.
39.
Olson BR, Drutarosky MD, Stricker EM, Verbalis JG: Brain oxytocin receptors mediate corticotropin releasing hormone-induced anorexia. Am J Physiol 1991;260:R448–R452.
40.
Dagnault A, Ouerghi D, Richard D: Treatment with α-helical CRF(9–41) prevents the anorectic effect of 17-β-estradiol. Brain Res Bull 1993;32:689–692.
41.
Bloch GJ, Surth SM, Akesson TR, Micevych PE: Estrogen-concentrating cells with cell groups of the medial preoptic area: Sex differences and co-localization with galanin-immunoreactive cells. Brain Res 1992;595:301–308.
42.
Bonavera JJ, Dube MG, Kalra PS, Kalra SP: Anorectic effects of estrogen may be mediated by decreased neuropeptide Y release in the hypothalamic paraventricular nucleus. Endocrinology 1994;134:2367–2370.
43.
Flanagan LM, McEwen BS (eds): Ovarian Steroid Interactions with Hypothalamic Oxytocin Circuits Involved in Reproductive Behavior. Neurobiological Effects of Sex Steroid Hormones. New York, Cambridge University Press, 1995, pp 117–142.
44.
Hoffman GE, Smith MS, Verbalis JG: c-Fos and related immediate early gene products as markers of activity in neuroendocrine systems. Front Neuroendocrinol 1993;14:173–213.
45.
Tolchard S, Ingram CD: Electrophysiological actions of oxytocin in the dorsal vagal complex of the female rat in vitro: Changing responsiveness during the oestrous cycle and after steroid treatment. Brain Res 1993;609:21–28.
46.
Tetel MJ, Getzinger MJ, Blaustein JD: Estradiol and progesterone influence the response of ventromedial hypothalamic neurons to tactile stimuli associated with female reproduction. Brain Res 1994;646:267–272.
47.
Pfaus JG, Marcangione C, Smith WJ, Manitt C, Abillamaa H: Differential induction of Fos in the female rat brain following different amounts of vaginocervical stimulation: Modulation by steroid hormones. Brain Res 1996;741:314–330.
48.
Conde GL, Herbison AE, Fernandez-Galaz C, Bicknell RJ: Estrogen uncouples noradrenergic activation of Fos expression in the female rat preoptic area. Brain Res 1996;735:197–207.
1998
Copyright / Drug Dosage / Disclaimer
Copyright: All rights reserved. No part of this publication may be translated into other languages, reproduced or utilized in any form or by any means, electronic or mechanical, including photocopying, recording, microcopying, or by any information storage and retrieval system, without permission in writing from the publisher.
Drug Dosage: The authors and the publisher have exerted every effort to ensure that drug selection and dosage set forth in this text are in accord with current recommendations and practice at the time of publication. However, in view of ongoing research, changes in government regulations, and the constant flow of information relating to drug therapy and drug reactions, the reader is urged to check the package insert for each drug for any changes in indications and dosage and for added warnings and precautions. This is particularly important when the recommended agent is a new and/or infrequently employed drug.
Disclaimer: The statements, opinions and data contained in this publication are solely those of the individual authors and contributors and not of the publishers and the editor(s). The appearance of advertisements or/and product references in the publication is not a warranty, endorsement, or approval of the products or services advertised or of their effectiveness, quality or safety. The publisher and the editor(s) disclaim responsibility for any injury to persons or property resulting from any ideas, methods, instructions or products referred to in the content or advertisements.
You do not currently have access to this content.